References in periodicals archive ?
ITM affiliate ITG Isotope Technologies Garching GmbH will develop radiolabeled DOTATOC for treatment of metastatic neuroendocrine tumors.
We evaluated microsomal aromatase activity by tritiated water release from the radiolabeled substrate (Dintinger et al.
Radiolabeled drugs are important for the diagnosis and treatment of multiple cancers.
The bacteria soon went to work "eating" the radiolabeled contaminants.
The Phase 1 study demonstrated that intravenously administered radiolabeled TM601 is able to cross the blood-brain barrier, specifically bind to tumor tissue, and is actively internalized by tumor cells, including metastases to the central nervous system.
Selection of the targeting antibody -- The rationale for choice of radioisotope -- Design and properties of chelators for optimal attachment of radio- metallic isotopes to antibodies -- Understanding process development and cGMP manufacturing of radiolabeled antibodies -- Preclinical design considerations for radiolabeled antibodies
MediPharm received product approval for Iodine-131 radiolabeled Tumor Necrosis Therapy (TNT) monoclonal antibody in the Peoples Republic of China.
Human Genome Sciences continues to investigate the potential of a radiolabeled BLyS protein therapeutic for certain B cell cancers, and plans to initiate a clinical program when appropriate.
Onalta, which has been studied in several clinical trials in the United States, is a radiolabeled peptide that the company intends to develop for the treatment of metastatic pancreatic neuroendocrine and carcinoid tumors in patients whose symptoms are not controlled by somatostatin analogue therapy.
HGS seeks to develop a radiolabeled BLyS complex for the treatment of B-cell malignancies such as chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
ZK-BA (Solazed[TM]) joins Azedra[TM] (Ultratrace[TM] iobenguane I 131) and Onalta[TM] (an yttrium-90 radiolabeled somatostatin peptide analog) in Molecular Insight's portfolio of targeted radiotherapeutic product candidates.
In this pharmacokinetics and tolerance study, which the company believes was the first systemic use of a radiolabeled antisense oligonucleotide, six HIV positive patients were administered radiolabeled GEM 91.